Quantitative Oncologic PET-MR

项目总结 这一竞争性续订应用程序的总体目标仍然侧重于开发和利用 利用PET和MR成像之间的协同作用进行定量分子成像的生物标记物 为肉瘤的肿瘤放射治疗(RT)提供显著改进的指导。传统上，定义 放射治疗靶区的部分利用CT和(有时)MR图像来描绘可见的肉眼肿瘤 体积(GTV)，根据临床情况将其扩展一定的边际以反映微观疾病 指南，形成临床靶区体积(CTV)。标准的T1/T2加权MR图像不能 区分肿瘤的浸润性和炎性，因此CTV中的水肿物是留给 医生的判断。 对于不能切除的患者，最终的RT导致失败的局部控制率仅为40%至75% 主要发生在肉眼肿瘤内。标准的解剖成像不允许识别位于 局部故障的风险。我们假设多参数PET/MR成像将有助于识别潜在的 为了给肿瘤内耐药细胞群开出更高的剂量，使这些区域增加 治疗效果。

PROJECT SUMMARY The overall goal of this competing renewal application remains focused on developing and leveraging quantitative molecular imaging biomarkers that take advantage of a synergy between PET and MR imaging to provide significantly improved guidance for cancer radiation therapy (RT) in sarcomas. Traditionally, definition of the radiotherapy target volume utilizes CT and (sometimes) MR images to delineate visible gross tumor volume (GTV) which is expanded by certain margins to account for microscopic disease according to clinical guidelines, forming the clinical target volume (CTV). The standard T1/T2 weighted MR images are unable to distinguish tumor infiltration from inflammation and therefore inclusion of edema into the CTV is left to the physician's judgment. For patients unable to have resection, definitive RT results in local control of only 40 to 75% with the failures occurring primarily within the gross tumor. Standard anatomic imaging does not allow identification of areas at risk of local failure. We hypothesize that multiparametric PET/MR imaging will help to identify potential areas of resistant cell populations within the tumor in order to prescribe the higher dose to these areas to increase treatment effectiveness.